Foundational Compliance Intelligence
A Subpart Analysis is a comprehensive report of all FDA 483 activity from 2017 through present for both pharmaceuticals (PharmaBenchmark) and devices (DeviceBenchmark). All Part 211 and Part 820 regulations are grouped by subpart with active links to current eCFR guidance. Each subpart is organized by regulation showing current 483 links from 2017 leveraging our proprietary database of FDA enforcement activity.
Current subscribers frequently cite the extensive research behind this resource and the concise way the information is presented. Organizations use it to benchmark performance, evaluate supplier opportunities, conduct risk analysis, and support both management reviews and strategic planning. Subscribers report discovering new applications for the data as they integrate it into their decision-making processes.
See the redacted example below.
| PART 211 CURRENT GOOD MANUFACTURING PRACTICE FOR FINISHED PHARMACEUTICALS |
| Subpart B–Organization and Personnel |
| § 211.22 – Responsibilities of quality control unit. |
| § 211.25 – Personnel qualifications |
| § 211.28 – Personnel responsibilities. |
| § 211.34 – Consultants |
Do you know how much exposure exists in your organization during regulatory and/or notified body inspections?
A streamlined Baseline Assessment based on validated best practices for Subpart B quality processes delivers within 10 days an objective score, actionable recommendations and strategic plan. This 2 min video explains baseline assessments https://youtu.be/JO_RWLzkCf8. Email info@complyfda.com or complete the baseline assessment request form at
www.complyfda.com to receive a free quote and complimentary consultation.
